Search

Your search keyword '"Coveler, Andrew"' showing total 18 results
Start Over Author "Coveler, Andrew" Publisher american society of clinical oncology
18 results on '"Coveler, Andrew"'

5. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.

Author

Verheij, Floris S., Omer, Dana M., Williams, Hannah, Lin, Sabrina T., Qin, Li-Xuan, Buckley, James T., Thompson, Hannah M., Yuval, Jonathan B., Kim, Jin K., Dunne, Richard F., Marcet, Jorge, Cataldo, Peter, Polite, Blase, Herzig, Daniel O., Liska, David, Oommen, Samuel, Friel, Charles M., Ternent, Charles, Coveler, Andrew L., and Hunt, Steven

Published
2024
Full Text
View/download PDF

6. Early results of a pancreas cancer learning health network: Canopy Cancer Collective.

Author

Herman, Joseph M., Alyesh, Abigail Zier, Korah, Bobby, Narang, Amol, Deperalta, Danielle, Lowy, Andrew M., Ejaz, Aslam, Tempero, Margaret A., Fisher, George A., Coveler, Andrew L., Aguilera, Todd Anthony, Goodman, Karyn A., Donahue, Timothy R., Leal, Alexis Diane, Malik, Nadia, Giles, Kurt, Roberts, Hannah Johnson, Hoffe, Sarah E., Hoos, William Arthur, and Stricker, Carrie Tompkins

Published
2024
Full Text
View/download PDF

10. Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).

Author

Mahalingam, Devalingam, Saeed, Anwaar, Powell, Steven Francis, Huerta Alvaro, Marisol, Sahai, Vaibhav, Coveler, Andrew L., Davis, Elizabeth J., Steeghs, Neeltje, Mulcahy, Mary Frances, Raufi, Alexander G, Cavalcante, Ludimila, Cervantes, Andres, Berlin, Jordan, Afanasjeva, Janna, Mikrut, William, Smith, Sheri Lynn, Giles, Francis J., and Carneiro, Benedito A.

Published
2023
Full Text
View/download PDF

11. Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.

Author

Coveler, Andrew L., Reilley, Matthew, Zalupski, Mark, Macarulla, Teresa, Fountzilas, Christos, Castanon Alvarez, Eduardo, Nagrial, Adnan, Uboha, Nataliya Volodymyrivna, Frentzas, Sophia, Overman, Michael J., Noonan, Anne M., Messersmith, Wells A., Pavlakis, Nick, Mettu, Niharika B., Smith, Paul, Murtomaki, Elina, Bragulat, Veronique, Cooper, Zachary A., Kumar, Rakesh, and Spigel, David

Published
2023
Full Text
View/download PDF

12. HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.

Author

Strickler, John H, Cercek, Andrea, Ng, Kimmie, Siena, Salvatore, Andre, Thierry, Van Cutsem, Eric, Wu, Christina, Paulson, Andrew Scott, Hubbard, Joleen M., Coveler, Andrew L., Fountzilas, Christos, Kardosh, Adel, Kasi, Pashtoon Murtaza, Lenz, Heinz-Josef, Ciombor, Kristen Keon, Elez, Elena, Stecher, Michael, Cronin, Pauline, Bieda, Mark, and Bekaii-Saab, Tanios S.

Published
2023
Full Text
View/download PDF

13. Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR T MSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA).

Author

Chiorean, E. Gabriela, Chapuis, Aude, Coveler, Andrew L., Yeung, Cecilia CS, Gooley, Ted, Zhen, David Bing, King, Gentry Teng, Hannan, Lindsay Marie, Cohen, Stacey A., Safyan, Rachael A, Germani, Anthony, Ra, Susan, Casserd, Jennifer, Schmitt, Thomas, and Greenberg, Philip D

Published
2023
Full Text
View/download PDF

15. HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial.

Author

Cercek, Andrea, Ng, Kimmie, Strickler, John H, Siena, Salvatore, Andre, Thierry, Van Cutsem, Eric, Wu, Christina, Paulson, Andrew Scott, Hubbard, Joleen M., Coveler, Andrew L., Fountzilas, Christos, Kardosh, Adel, Kasi, Pashtoon Murtaza, Lenz, Heinz-Josef, Ciombor, Kristen Keon, Elez, Elena, Stecher, Michael, Cronin, Pauline, Feng, Wentao, and Bekaii-Saab, Tanios S.

Published
2023
Full Text
View/download PDF

16. Building a learning network to accelerate improvement in pancreas cancer care and outcomes: Canopy Cancer Collective.

Author

Herman, Joseph M., Stricker, Carrie Tompkins, Myers, Sarah, Korah, Bobby, Narang, Amol, Hacker-Prietz, Amy, Deperalta, Danielle, Hong, Theodore S., Dullard, Amy, Lowy, Andrew, Ejaz, Aslam, Tempero, Margaret A., Fisher, George A., Coveler, Andrew L., King, Daniel, Pinto, Danielle, Meguid, Cheryl, Aguilera, Todd Anthony, Hoos, William Arthur, and Margolis, Peter

Published
2022
Full Text
View/download PDF

17. Localized Pancreatic Cancer: Multidisciplinary Management.

Author

Coveler AL, Herman JM, Simeone DM, and Chiorean EG

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Camptothecin analogs & derivatives, Camptothecin therapeutic use, Combined Modality Therapy, Fluorouracil therapeutic use, Humans, Leucovorin therapeutic use, Neoadjuvant Therapy, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local radiotherapy, Pancreatectomy, Pancreatic Neoplasms pathology, Pancreatic Neoplasms radiotherapy, Radiosurgery, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms surgery
Abstract

Pancreatic cancer is an aggressive cancer that continues to have single-digit 5-year mortality rates despite advancements in the field. Surgery remains the only curative treatment; however, most patients present with late-stage disease deemed unresectable, either due to extensive local vascular involvement or the presence of distant metastasis. Resection guidelines that include a borderline resectable group, as well as advancements in neoadjuvant chemotherapy and radiation that improve resectability of locally advanced disease, may improve outcomes for patients with more invasive disease. Multi-agent chemotherapy regimens fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and nab-paclitaxel with gemcitabine improved response rates and survival in metastatic pancreatic cancer and are now being used in earlier stages for patients with localized potentially resectable and unresectable disease, with goals of downstaging tumors to allow margin-negative resection and reducing systemic recurrence. Chemoradiotherapy, although still controversial for both resectable and unresectable pancreatic cancer, is being used in the context of contemporary chemotherapy backbone regimens, and novel radiation techniques such as stereotactic body frame radiation therapy (SBRT) are studied on the premise of maintaining or improving efficacy and reducing treatment duration. Patient selection for optimal treatment designation is currently provided by multidisciplinary tumor boards, but biomarker discovery, in blood, tumors, or through novel imaging, is an area of intense research. Results to date suggest that some patients with unresectable disease at the outset have survival rates as good as those with initially resectable disease if able to undergo surgical resection. Long-term follow-up and improved clinical trials options are needed to determine optimal treatment modalities for patients with localized pancreatic cancer.

Published
2016
Full Text
View/download PDF

18. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.

Author

Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, dela Rosa C, Tietje K, Link J, Waisman J, and Salazar LG

Subjects
Adult, Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Breast Neoplasms immunology, Breast Neoplasms pathology, Cancer Vaccines administration & dosage, Cancer Vaccines immunology, Combined Modality Therapy, Fatigue etiology, Female, Headache etiology, Humans, Kaplan-Meier Estimate, Middle Aged, Molecular Sequence Data, Neoplasm Metastasis, Pain etiology, Peptides chemistry, Peptides immunology, Receptor, ErbB-2 chemistry, T-Lymphocytes drug effects, T-Lymphocytes immunology, Transforming Growth Factor beta blood, Trastuzumab, Treatment Outcome, Vaccination adverse effects, Antibodies, Monoclonal therapeutic use, Breast Neoplasms therapy, Receptor, ErbB-2 immunology, Vaccination methods
Abstract

Purpose: The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast cancer., Patients and Methods: Twenty-two patients with stage IV HER2/neu-positive breast cancer receiving trastuzumab therapy were vaccinated with an HER2/neu T-helper peptide-based vaccine. Toxicity was graded according to National Cancer Institute criteria, and antigen specific T-cell immunity was assessed by interferon gamma enzyme-linked immunosorbent spot assay. Data on progression-free and overall survival were collected., Results: Concurrent trastuzumab and HER2/neu vaccinations were well tolerated, with 15% of patients experiencing an asymptomatic decline in left ventricular ejection fraction below the normal range during combination therapy. Although many patients had pre-existing immunity specific for HER2/neu and other breast cancer antigens while treated with trastuzumab alone, that immunity could be significantly boosted and maintained with vaccination. Epitope spreading within HER2/neu and to additional tumor-related proteins was stimulated by immunization, and the magnitude of the T-cell response generated was significantly inversely correlated with serum transforming growth factor beta levels. At a median follow-up of 36 months from the first vaccine, the median overall survival in the study population has not been reached., Conclusion: Combination therapy with trastuzumab and a HER2/neu vaccine is associated with minimal toxicity and results in prolonged, robust, antigen-specific immune responses in treated patients.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results